Antibody-dependent enhancement of virus infection and disease: implications in COVID-19.
J Basic Clin Physiol Pharmacol
; 33(1): 13-16, 2022 Jan 07.
Article
in English
| MEDLINE | ID: covidwho-1613395
ABSTRACT
Antibody-dependent enhancement (ADE) can be seen in a variety of viruses. It has a deleterious impact on antibody treatment of viral infection. This effect was first discovered in the dengue virus, and it has since been discovered in the coronavirus. Over 213 million people have been affected by the rapid spread of the newly emerging coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19). The new coronavirus offers a significant threat and has sparked widespread concern. ADE in dengue virus and other viruses are discussed with possible effect on COVID-19 treatment and vaccine development will need to consider this phenomenon to ensure it is mitigated and avoided altogether. In these case scenarios, the role of ADE and its clinical consequences remains to be explored for this newly detected virus.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antibody-Dependent Enhancement
/
COVID-19
/
COVID-19 Drug Treatment
Type of study:
Prognostic study
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
J Basic Clin Physiol Pharmacol
Journal subject:
Pharmacology
/
Physiology
Year:
2022
Document Type:
Article
Affiliation country:
Jbcpp-2021-0264
Similar
MEDLINE
...
LILACS
LIS